The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2025 | The ideal trial on the road to achieving the best outcome for patients with myeloma
In this video, Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, briefly comments on the ideal trial design on the road to achieving the best outcome for patients with multiple myeloma (MM), highlighting the need to change the model that has been used in previous clinical trials. This interview took place at the 11th World Congress on Controversies in Multiple Myeloma (COMy) congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, I think when we’re talking about ideal trial design, there are a couple of factors involved here. The first is we know that data from the PERSEUS trial, particularly with modeling studies, suggests the median PFS is somewhere between 10 and 15 years for all patients. So I think building on that certainly makes sense. But ultimately, if we’re going to cure patients, I think we have to change the model...
Well, I think when we’re talking about ideal trial design, there are a couple of factors involved here. The first is we know that data from the PERSEUS trial, particularly with modeling studies, suggests the median PFS is somewhere between 10 and 15 years for all patients. So I think building on that certainly makes sense. But ultimately, if we’re going to cure patients, I think we have to change the model. We certainly are excited about a trial we’re proposing that totally changes the model, uses multiple immune targets over a two-year period, and then stops therapy with the hope of curing myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
